Envisioning the Future of Pathology in Precision Oncology

Personalized medicine driven by genomic-based treatments continues to increase in importance. A representative from a regional reference lab provides his perspective on how they approach the challenge of addressing this need. The speaker will present on the reasons why they chose to internalize NGS testing, the value it brings to their healthcare system/network and what was involved to actualize their programs. Digital analytics and analysis employed by LTS Health was incorporated to provide feedback on the impact to laboratory operations and forecasting for future growth.  

Tony Magliocco, MD, Executive Director of the Advanced Diagnostic Laboratories, Moffitt Cancer Center, has over 25 years experience as a Professor, Researcher, Pathologist, Laboratory Director, Consultant, Tissue Banker, and public speaker. He is Board Certified in Anatomic Pathology and has extensive experience and sub-specialty expertise in Breast, Gyn, and Molecular Pathology. He has held continuous peer reviewed funding in translational research and his laboratory is currently investigating the mechanisms of ovarian cancer metastasis and treatment evasion. He has founded numerous molecular diagnostic laboratories in the USA and Canada, has published over 200 manuscripts in oncology, and holds numerous diagnostic technology patents. He is currently Executive Director of Esoteric Laboratory Services at the Moffitt Cancer, as well as Scientific Director for Moffitt Tissue Core, one of the largest bio banking programs in the world. He also directs the newly formed Moffitt Morsani Advanced Diagnostics Laboratories which is focused on accelerating development of new CLIA laboratory diagnostics. Dr Magliocco also directs fellowship programs in Molecular Diagnostics and Digital Pathology. He has held numerous national and international roles including Chair of Pathology for the Radiation Therapy and Oncology Clinical Trials group, member of the NCI GU steering committee, and member of the Canadian Cancer Clinical Trials Network Steering committee, as well as previous editorial position with the Journal of Surgical Oncology and is frequent reviewer for numerous other Oncology and Pathology Journals.